Name | (8S)-7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid |
---|---|
Synonyms |
Renormax
Spirapril [INN:BAN] Espirapril [Spanish] Setrilan Spirapril (INN) Not established Spiraprilum [Latin] Sandopril Spirapril |
Description | Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active prodrug of Spiraprilat and can be used for the research of hypertension, congestive heart failure[1][2][3]. |
---|---|
Related Catalog | |
In Vivo | Spirapril (feeding needle; 10 mg/kg; 3 weeks) decreases alcohol intake in TGM123 mice and dose not reduce the alcohol consumption in TLM mice[2]. Spirapril shows a 40.2% reduction in ACE activity in brain membrane from treated-mice[2]. Spirapril can crosses the blood-brain barrier and suppresses the transgene effect in the experiments[2]. Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats[3]. |
References |
[2]. Maul B, et al. Alcohol consumption is controlled by angiotensin II. FASEB J. 2001 Jul;15(9):1640-2. |
Density | 1.32 g/cm3 |
---|---|
Boiling Point | 697.8ºC at 760 mmHg |
Molecular Formula | C22H30N2O5S2 |
Molecular Weight | 466.61400 |
Flash Point | 375.8ºC |
Exact Mass | 466.16000 |
PSA | 146.54000 |
LogP | 2.71960 |
Index of Refraction | 1.621 |
Storage condition | -20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Precursor 8 | |
---|---|
DownStream 1 | |